Aytu BioPharma Q1 EPS $(1.48) Down From $(1.20) YoY, Sales $22.10M Miss $27.73M Estimate
Portfolio Pulse from bharat@benzinga.com
Aytu BioPharma (NASDAQ:AYTU) reported a larger Q1 loss of $(1.48) per share compared to $(1.20) per share in the same quarter last year. Sales for the quarter were $22.10M, which fell short of the analyst consensus estimate of $27.73M by 20.31%, and represented a 20.09% decrease from the $27.66M reported in the same period last year.
November 14, 2023 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aytu BioPharma reported a larger Q1 loss and a significant miss in sales estimates, indicating potential negative investor sentiment in the short term.
The reported increase in losses and the miss on sales estimates are likely to be viewed negatively by investors, potentially leading to a decrease in stock price in the short term. The magnitude of the miss and the year-over-year decline in sales are significant factors that could drive investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100